Bio­phar­ma in­dus­try's vac­cine pipeline lacks ‘depth,' with an overem­pha­sis on Covid — re­port

There are too many Covid vac­cines in de­vel­op­ment, and many oth­er in­fec­tious dis­eases where lit­tle work is get­ting done by biotech and phar­ma com­pa­nies.

That’s the con­clu­sion of a new re­port from the Biotech­nol­o­gy In­no­va­tion Or­ga­ni­za­tion, or BIO, which found that of the 249 nov­el vac­cine pro­grams be­ing test­ed in hu­mans around the world, 28% were for the pre­ven­tion of Covid-19. On­ly 20% of dis­eases have five or more on­go­ing clin­i­cal pro­grams. And some preva­lent threats, like West Nile virus and Ly­me dis­ease, have just one vac­cine in clin­i­cal de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER